March 5, 2018 / 12:34 PM / 3 months ago

Clearside Biomedical's eye treatment succeeds late-stage study

March 5 (Reuters) - Clearside Biomedical Inc said on Monday its treatment for fluid build-up in the eye had met the main goal of a late-stage study.

Shares of the Alpharetta, Georgia-based drug developer jumped 52.2 percent at $11.90 in premarket trading.

The drug was being tested in patients with macular edema associated with non-infectious uveitis.

Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below